|
CID16020046
- 品牌：MedKoo
- 產(chǎn)地：美國
- 貨號(hào)：513693
- cas：834903-43-4
- 發(fā)布日期： 2022-07-20
- 更新日期： 2024-08-12
產(chǎn)品詳請(qǐng)
| 產(chǎn)地 | 美國 |
| 品牌 | MedKoo |
| 貨號(hào) | 513693 |
| 用途 | This product is for research use only, not for human or veterinary use. |
| 包裝規(guī)格 | 25.0mg; 50.0mg; 100.0mg; 200.0mg; 500.0mg; 1.0g; 2.0g; |
| CAS編號(hào) | 834903-43-4 |
| 純度 | >98%% |
| 是否進(jìn)口 | 是 |
中文名稱:4-[4,6-二氫-4-(3-羥基苯基)-3-(4-甲基苯基)-6-氧代吡咯并[3,4-C]吡唑-5(1H)-基]苯甲酸
CAS No:834903-43-4
分子式:C25H19N3O4
沸點(diǎn):748.1±60.0 °C(Predicted)
密度:1.425±0.06 g/cm3(Predicted)
用途:CID 16020046 is a selective GPR55 antagonist. It Inhibits LPI-induced Ca2+ signaling, ERK1/2 phosphorylation and GPR55-mediated transcription factor activation. It displays weak inhibition of acetylcholinesterase, μ-opioid receptor, KCNH2 and hERG. It decreases LPI-induced GPR55 internalization. CI..
安全說明:26
CAS No:834903-43-4
分子式:C25H19N3O4
沸點(diǎn):748.1±60.0 °C(Predicted)
密度:1.425±0.06 g/cm3(Predicted)
用途:CID 16020046 is a selective GPR55 antagonist. It Inhibits LPI-induced Ca2+ signaling, ERK1/2 phosphorylation and GPR55-mediated transcription factor activation. It displays weak inhibition of acetylcholinesterase, μ-opioid receptor, KCNH2 and hERG. It decreases LPI-induced GPR55 internalization. CI..
安全說明:26
相關(guān)產(chǎn)品：
